Skip to content

Cognitive therapy for body dysmorphic disorder

Cognitive Therapy for Body Dysmorphic Disorder (CT-BDD): a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN92515063
Enrollment
38
Registered
2017-05-12
Start date
2016-09-01
Completion date
Unknown
Last updated
2022-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Body dysmorphic disorder Mental and Behavioural Disorders Hypochondriacal disorder

Interventions

Current interventions as of 17/08/2021: Thirty-eight adults with a primary diagnosis of BDD will be randomized to 20 sessions (25x50 units) of individual CT-BDD over 9 months or to a 3
Wei, 1978). Randomization is stratified by pretreatment delusionality (as assessed by the BABS). Cognitive therapy for BDD (CT-BDD) includes interventions that aim at modifying biased
Wei, 1978). Randomization is stratified by pretreatment delusionality (as assessed by the BABS). Cognitive therapy for BDD (CT-BDD) includes interventio

Sponsors

Deutsche Forschungsgemeinschaft (DFG)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Primary diagnosis of body dysmorphic disorder (BDD) according to the Body Dysmorphic Disorder Diagnostic Module (BDDDM adapted for DSM-5), the Structured Interview for Diagnostic and Statistical Manual of Mental Disorders – Fifth Edition (SCID-I DSM-5) and the Yale-Brown Obsessive-Compulsive Scale Modified for BDD (BDD-YBOCS) = 20 2. BDD symptoms for at least 6 months prior to participation 3. Age 18-70 years 4. Either no psychotropic medication or, if taking psychotropic medication, be on a stable dose for at least 2 months prior to initial evaluation and agreement not to change the medication during the study 5. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Acute suicidality 2. Psychotic disorder (excluding delusional BDD) 3. Bipolar disorder 4. Alcohol or substance dependence within the last 3 months 5. Borderline personality disorder 6. Prominent risk of self-harm 7. Body image/weight concerns accounted primarily by an eating disorder 8. Organic mental disorder 9. Severe medical conditions 10. Concurrent psychotherapeutic treatment (e.g., psychodynamic)

Design outcomes

Primary

MeasureTime frame
For A1: 1. BDD symptom severity, measured using the clinician-administered Body Dysmorphic Disorder Modification of the Yale-Brown Obsessive-Compulsive Scale (BDD-YBOCS) 2. BDD diagnosis, measured using the clinician-administered BDD Diagnostic Module (BDDDM) Measured at pretreatment, 12 weeks/post-WL, 24 weeks, post treatment, 3- and 6-months follow-up

Secondary

MeasureTime frame
For A1: 1. Insight, measured using the Brown Assessment of Beliefs Scale (BABS) at pre, 12-weeks/post-WL, 24 weeks, post, 3- and 6-month follow-up 2. Depression, measured using the Quick Inventory of Depressive Symptoms (QUIDS-C), Beck Depression Inventory-II (BDI-II) at pre, 12-weeks/post-WL, 24 weeks, post, 3- and 6-month follow-up 3. Psychosocial functioning, measured using the Global Assessment of Functioning Scale (GAF) at pre, 12-weeks/post-WL, 24 weeks, post, 3- and 6-month follow-up 4. Body dysmorphic concerns, measured using the Body Dysmorphic Symptoms Symptoms Inventory, Fragebogen körperdysmorpher Symptome (FKS) at pre, 12-weeks/post-WL, 24 weeks, post, 3- and 6-month follow-up 5. General symptomatology, measured using the Brief Symptom Inventory (BSI) at pre, 12-weeks/post-WL, 24 weeks, post, 3- and 6-month follow-up 6. Quality of life, measured using the EUROHIS Quality-of-Life Index (EUROHIS-QOL) at pre, 12-weeks/post-WL, 24 weeks, post, 3- and 6-month follow-up For B1: 1. Emotion regulation, measured using the clinician-administered Operationalized Skills Assessment Inventory, Emotion Regulation adapted for BDD (OFD-ER-BDD) at pre, 12 weeks/post-WL, post 2. Attachment characteristics, measured using the clinician-administered Adult Attachment Interview, Erwachsenen-Bindungsprototypen-Rating (EBPR-BI) at pre 3. Self-reported attachment, measured using the self-report questionnaire Experiences in Close Relationships-Revised (ECR-R) at pre, 12 weeks/post-WL, 24 weeks, post, 3- and 6-months follow-up For C1: 1. Implicit shame, measured using an Implicit Association Test (IAT) at pre, post-WL, post 2. Explicit shame, measured using the Body-Focused Shame and Guilt Scale (BFSGS) at pre, post-WL, post 3. Social pain, measured using the

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026